6th Annual

TRP

TARGETED RADIOPHARMACEUTICALS SUMMIT EUROPE

3rd - 5th December 2024
Amsterdam, Netherlands

2 Tracks of Content

40+ Expert Speakers

140+ Attendees

Unlocking Novel Radiopharmaceutical Targeting Mechanisms to Expand Across More Indications While Navigating the Diverse European Regulatory Landscape, Maximising Positive Clinical Momentum & Advancing Supply Chain Expertise

40+ World-Class Speakers, Including:

Jens De Vos
Head of Alliance & Program Management
Precirix

Evrim Gurpinar
Senior Director, Oncology R&D Business Development
AstraZeneca

Jasminka Taleska
Global Director RLT HCS Readiness & RLT Policy Strategy
Novartis

Julien Torgue
Chief Scientific Officer
OranoMed

Ken Herrmann
Professor
University Hospital Essen

Ming Xu
Vice President, Product Team Leader (PTL) for RED Oncology
Bayer

Vicki Jardine
Vice President - Clinical Development
ARTBIO

Goekben Koca
Chief Medical Officer
Mariana Oncology

Proud to Partner With:

PSI · itm PASSION FOR PRECISION · BIOEMTECH · Navigo Proteins · PharmaLogic Take The Lead · SHINE · Chelatec · TRASIS · IONETIX · AtomVie Global Radiopharma · NorthStar Medical Radioisotopes, LLC · time:matters

+44 (0)20 3141 8700 | info@hansonwade.com | www.targeted-radiopharma.com | Targeted Radiopharmaceuticals

hansonwade

BOOK BY FRIDAY, 25TH OCTOBER & SAVE €600

CONTENTS

Welcome to the 6th TRP Summit Europe

This year has been *the year* for radiopharmaceuticals. More patients being treated by Pluvicto and Lutathera than ever before, companies advancing their pipelines across a range of targeting moieties, radioisotopes and novel targets including DLL3 and NTSR1 - and that's not to mention the flood of billion-dollar acquisitions and investments from **Novartis**, **AstraZeneca**, **Eli Lilly** and **BMS** strengthening the field!

The **6th Targeted Radiopharmaceuticals Summit Europe** is the longest standing industry focused meeting delivering an end-to-end overview of this highly competitive and dynamic landscape. Uncover **novel target** development beyond validated PSMA and SSTR2 to reach **more indications**, expand **targeting moieties** to enhance tumour penetration and discover key case studies from **designing a first in human** radiopharmaceutical trial as well as applying **dosimetry** to optimise dosing.

Join your scientific community to explore how Europe can keep up with fast paced innovation by reaching **regulatory clarity** while analysing the **US-Europe intersection** across pressing clinical and **supply chain** challenges to keep your global trials moving. Bringing together insights from the leading radiopharmaceutical minds across **pharma**, **biotech**, **academia**, and **clinicians** from **discovery**, **preclinical**, **clinical**, **CMC** and **supply chain** this is your opportunity to network and learn from the experts.

Gathering world-class speakers to address the most exciting opportunities and challenges spanning novel targeting mechanisms, alpha vs beta emitters, nuclear medicine clinical expertise, isotope supply, European logistics chains as well as pricing and reimbursement - don't miss the biggest edition of the ***6th Targeted Radiopharmaceuticals Europe Summit*** to date!

Sincerely,

Lily Haring

Senior Program Director

Hanson Wade

Attend the 6th TRP Europe Summit to:

Unearthing novel targets for radiopharmaceuticals from DLL3, AVB8 and PDL-1 with Philochem and Orano Med while revealing cutting-edge targeting moieties for enhanced specificity and efficacy from **Starget Pharma** and **Star Pharma**

Interrogating isotope comparison data to understand the optimal blend of biological half-life, physical half-life and targeting moiety while exploring immune profiles stimulated with **OranoMed** and **Ariceum**

Understanding what it really means to be health system ready when implementing radiopharmaceuticals into hospitals with **Novartis** and influencing health care policy and pricing and reimbursement to expand patient access

Turbocharging your manufacturing safety, quality and efficiency exploring novel isolation technologies and new processes with **ARTBIO** and **RadioPharm Theranostics** and measuring alphas in the clinic

Assessing dosimetry regulatory guidelines and exploring exactly how it should be implemented into the clinic for enhanced patient safety and efficacy with **Bayer**, **Lund University**, **Institute of Cancer Research** and more

"High quality of speakers and presentations, true experts in their field, broad range of topics, enough space for networking, workshops plus site visit a great add-on"

Roche

BOOK BY FRIDAY, 25TH OCTOBER & SAVE €600

CONTENTS

WELCOME

AGENDA AT A GLANCE

EXPERT SPEAKERS

PRE-CONFERENCE WORKSHOP DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

PARTNER WITH US

PARTNERS

2024 Expert Speakers

6th Annual TRP TARGETED RADIOPHARMACEUTICALS SUMMIT EUROPE

3rd - 5th December 2024
Amsterdam, Netherlands

Caitlyn Harvey
Vice President, Head of CMC
Convergent Therapeutics

Caroline Stokke
Associate Professor
Oslo University Hospital

Chris Leamon
Chief Scientific Officer
Fusion Pharmaceuticals

Daniel Rossetto
Senior Vice President & Head Of Supply Chain & External Manufacturing
ARTBIO

Daniel Steiner
Senior Vice President Research & Technology
Molecular Partners

Dirk Pleimes
Chief Medical & Scientific Officer
PentixaPharm

Evrim Gurpinar
Senior Director, Oncology R&D Business Development
AstraZeneca

Francesco De Rose
Head of Pharmaceutical Development
Nuclidium

Glenn Flux
Head of Radioisotope Physics
Institute of Cancer Research



Goekben Koca
Chief Medical Officer
Mariana Oncology

RayzeBio
A Bristol Myers Squibb Company

Isaac Simmonds
Associate Director of Radiochemistry
RayzeBio

Jasminka Taleska
Global Director RLT HCS Readiness & RLT Policy Strategy
Novartis

Jeevan Virk
RLT Therapeutic Area Strategy Head
Novartis

Jenny Karlsson
Senior Director Targeted Radiopharmaceuticals
Bayer

Jens De Vos
Head of Alliance & Program Management
Precirix

Jeremy Paull
Vice President - Development & Regulatory Affairs
Starpharma

Julie Nonnekens
Associate Professor Radiobiology of Radionuclide Therapy
Erasmus MC

Julien Torgue
Chief Scientific Officer
OranoMed

Justine Perrin
Post-doctoral Researcher
Erasmus MC

Katarina Sjogreen Gleisner
Professor
Lund University

Ken Herrmann
Professor
University Hospital Essen

Laila Quere
Co-Founder & Chief Executive Officer
aKen medical

Laurent Durous
Process Analytical Technology Scientist
Bayer

Leonhard Schaetz
International Head Health System Readiness & Partnership (RLT),
Novartis

BOOK BY FRIDAY, 25TH OCTOBER & SAVE €600

CONTENTS

2024 Expert Speakers

Luke Brzozowski
Executive Director, Translational Research & Core Facilities
University Health Network Canada

Manfred Rüdiger
Chief Executive Officer
Ariceum Therapeutics

Marc Robillard
Chief Executive Officer
Tagworks Pharmaceuticals

Marika Nestor
Chief Executive Officer
Akiram Therapeutics

Michel Afargan
Head of Drug Development
Starget Pharma

Ming Xu
Vice President, Product Team Leader (PTL) for RED Oncology
Bayer

Munir Ghesani
Chief Medical Officer
United Theranostic

Neydher Berroteran-Infante
Director - Chemistry, Manufacturing & Controls
PentixaPharm



Nina Eissler
Director Translational Medicine
Affibody

Riccardo Canevari
Chief Executive Officer
RadioPharm Theranostics

Samuele Cazzamalli
Head of Chemistry
Philochem

Sigal Kalmanson Cusnir
Chief Executive Officer
Starget Pharma

Vicki Jardine
Vice President - Clinical Development
ARTBIO

Vimal Patel
Vice President, CMC
RadioPharm Theranostics

Vineet Prakash
Medical Consultant
Royal Surrey County Hospital

> "Great sessions with speakers addressing relevant industry issues. Also, really good engagement with senior level biotech attendees."
> **Ionetix**

Agenda at a Glance

6th Annual TRP TARGETED RADIOPHARMACEUTICALS SUMMIT EUROPE
3rd - 5th December 2024
Amsterdam, Netherlands

PRE-CONFERENCE WORKSHOPS
TUESDAY, 3RD DECEMBER

Workshop A

Meeting your Match: Examining Physical Properties of **Isotopes** to Understand Their Effect Across Varying **Disease Characteristics**

Workshop B

Expanding Radiopharmaceutical Targeting Mechanisms with **Novel Moieties** to Harness Enhanced Specificity, Efficacy & Safety

Workshop C

Designing Optimal First in Human Radiopharmaceutical Trials for Translational Success: Regulatory Considerations

Workshop D

Implementing Targeted Radiopharmaceuticals into More **Hospitals** to Expand Access from Clinic to Approval

Workshop E

Enhancing Excellence & Execution While Working with Different Radiopharmaceutical **Supply Chain & Manufacturing** Players

Workshop F

Understanding **Alpha Toxicities: Mechanistic Understandings**, Safety & Measuring & Sustaining Clinical Quality Control

CONFERENCE DAY ONE
WEDNESDAY, 4TH DECEMBER

An Evolving European Market: Growing Radiopharmaceuticals Through Cross-Industry Learnings

Breaking Down Europe's Radiopharmaceuticals Landscape & Building on Learnings to Accelerate the Growing Field

Preclinical & Translational Track	Clinical & Supply Chain Track
Uncovering Trailblazing **Preclinical** Developments Opening up Novel Directions for the Radiopharmaceuticals Field	Transforming Clinical Understandings to Accelerate Radiopharmaceutical Development & **Expand Treatment Efficacy**
Lunch Break & Networking	
Ensuring **Translational Success** from Animal to Human Through Strategic Study Design & Expert Rationale	Securing **Radioisotope Production** Capabilities to Maximise Development
Afternoon Break & Networking	

Maximising Dosimetry Data to Optimise Dosing & Improve Patient Outcomes While Assessing European Funding

Interrogating Dose Limits to Push Beyond External Beam Dosing

End of Conference Day One

CONFERENCE DAY TWO
THURSDAY, 5TH DECEMBER

Shaping Healthcare Policy & Engaging Hospitals to Expand Access Across More Patients in Need

Obstacles & Opportunities in the Pricing & Reimbursement of Radiopharmaceuticals Across European Countries: Comparing UK, France & Germany

Preclinical & Translational Track	Clinical & Supply Chain Track
Finetuning **Dosing & Toxicity** Considerations for Radiopharmaceuticals to Ensure Patient Safety	Strengthening Your Radiopharmaceutical Production & **Transport Expertise** to Ensure no Trial Hold Up
Lunch Break & Networking	
Supercharging the Field by Exploring **Novel Radiopharmaceutical Targets**	Expanding **Combination Based Approaches** to Maximise Clinical Efficacy of TRPs
Afternoon Break & Networking	

Amplifying the Field: Spanning More Targets & Advancing Indications with Radiopharmaceuticals

End of Conference

Pre-Conference Workshop Day | Tuesday, 3rd December 2024

7.30 Check-in & Light Breakfast

Workshop A

8.30 MeetingYour Match: Examining Physical Properties of Isotopes to Understand Their Effect Across Varying Disease Characteristics

Selecting the appropriate isotope for targeted radiotherapy involves a thorough understanding of both the **properties of the isotopes** and the specific **characteristics of the disease** being treated. This requires an integration of knowledge from nuclear physics, oncology, and immunohistopathology.

In this workshop, we will delve into considerations for isotope selection to bring optimal treatment outcomes:

- Matching isotope properties with disease properties by examining **radiation type** and energy from **alpha**, **beta** and **gamma** emitters
- Exploring effects of **isotope half-life** and **decay pathways**, from short-lived to long-lived isotopes
- Assessing the optimal blend of **biological half-life**, **physical half-life and targeting moiety**
- Navigating criteria to be considered for isotope selection such as **tumour type** and location and **microenvironmental features**
- Outlining **targeting mechanisms** delivering the isotope to the tumour and considerations for optimal isotope selection
- Understanding **immune profiles** stimulated - activation and recruitment of immune cells at the tumor site after radionuclide therapy, and impact of the treatment on tumor immune resistance

Manfred Rüdiger, Chief Executive Officer, **Ariceum**

Julien Togue, Chief Scientific Officer, **OranoMed**

Justine Perrin, Post-doctoral Researcher, **Erasmus MC**

OR

Workshop D

8.30 Implementing Targeted Radiopharmaceuticals into More Hospitals to Expand Access From Clinic to Approval

Integrating targeted radiopharmaceuticals into hospitals involves ensuring **healthcare readiness**, adapting **hospital infrastructure** for **nuclear medicine**, addressing the specific requirements for handling alpha emitters, and developing strategies to increase the availability and use of radiopharmaceuticals in healthcare settings.

Expert teams will uncover:

- What it means to have **healthcare readiness** from clinical integration with interdisciplinary teams and clinical protocols, training and readiness
- Exploring how to effectively **adapt hospitals** for **nuclear medicine** looking at the infrastructure requirements, dedicated facilities and radiation safety measures
- Understanding scope around **compassionate use** programs
- Engaging with **policymakers** and **regulatory bodies** to advocate for supportive policies and regulations that facilitate the adoption and use of radiopharmaceuticals in clinical practice

Leonhard Schaetz, International Head Health System Readiness & Partnership (RLT), **Novartis**

Jasminka Taleska, Global Director RLT HCS Readiness & RLT Policy Strategy, **Novartis**

Vineet Prakash, Medical Consultant, **Royal Surrey NHS Foundation Trust**

Luke Brzozowski, Executive Director, Translational Research & Core Facilities, **University Health Network Canada**

10.30 Morning Break & Refreshments

> "I enjoyed the content and mixture of talks / attendees from different fields of radiopharmaceuticals. The panel discussions were very valuable and interesting"
>
> **Bicycle Therapeutics**

Pre-Conference Workshop Day | Tuesday, 3rd December 2024

Workshop B

11.00 Expanding Radiopharmaceutical Targeting Mechanisms with Novel Moieties to Harness Enhanced Specificity, Efficacy & Safety

The development of novel targeting moieties for radiopharmaceuticals has seen significant advancements, particularly in the context of targeting cancer cells and supporting tissues. These novel moieties include **small peptides**, **cyclic peptides, bispecifics and nanobodies**, each offering unique advantages in terms of **specificity**, **stability**, and **pharmacokinetics**.

Uncovering the latest understandings and developments across novel targeting approaches, this workshop will:

- Reveal more novel **small peptides** for enhanced specificity, affinity and rapid clearance
- Explore **cyclic peptides** for degradation resistance, improved binding and extended **circulation time**
- Interrogate **nanobodies** for better **tissue penetration** and rapid clearance and **high stability**
- Maximise**bispecifi**c antibodies for synergistic effects
- Examine existing **targeting mechanisms** such as **antibodies** and **antibody fragments** to assess their viability as isotope conjugates
- What should you be looking for to understand what makes a good targeting moiety

Michel Afargan, Head of Drug Development, **Starget Pharma**

Jeremy Paull, Vice President - Development & Regulatory Affairs, **Starpharma**

OR

Workshop E

11.00 Enhancing Excellence & Execution While Working with Different Radiopharmaceutical Supply Chain & Manufacturing Players

Developing and delivering radiopharmaceuticals requires seamless coordination with various **supply chain and manufacturing** players. This involves ensuring that all parties have the right capabilities and expertise to maintain **quality**, **safety**, and **efficiency** throughout the process. Both in-house teams and external players must work together efficiently to delivery high quality radiopharmaceuticals.

This workshop will provide key learnings, case-studies and expert insights addressing:

- Building a team of highly trained and quality **supply chain** and **manufacturing** personnel
- Exploring best practices for CDMO selection and management
- Drilling into technical expertise and learnings to drive strong **technology transfer** and regulatory navigation
- Developing strong **communications** with partners to drive streamlined information sharing

Daniel Rosetto, Senior Vice President- Head of Supply Chain & External Manufacturing, **ARTBIO**

Vimal Patel, Vice President, CMC, **RadioPharm Theranostics**

Neydher Berroteran-Infante, Director - Chemistry, Manufacturing & Controls, **PentixaPharm**

1.00 Lunch & Networking Break

Workshop C

2.00 Designing Optimal First in Human Radiopharmaceutical Trials for Translational Success: Regulatory Considerations

First-in-human radiopharmaceutical trials are critical for assessing the **safety**, **pharmacokinetics**, **dosimetry**, and **preliminary efficacy of new radiopharmaceuticals**. The design of these trials must be meticulous to ensure patient safety while gathering essential data. Key components include patient monitoring duration, dose toxicity assessment, and primary readouts.
Join this workshop to:

- Uncover **pre**, **during** and **post-treatment** monitoring
- Determine your **dose escalation** and safety reviews
- Exploring dosimetry from **absorbed dose calculation** and **dose response** relationships
- Dealing with **waste disposal**, **radiation safety** and logistical challenges with alpha emitters
- Considerations for **Project Optimus**

Francesco De Rose, Head of Pharmaceutical Development, **Nuclideum**

Ming Xu, Vice President, Product Team Leader (PTL) for RED Oncology, **Bayer**

OR

Workshop F

2.00 Ensuring Radiopharmaceutical Quality: Mechanistic Understandings, Safety & Measuring & Sustaining Drug Product Quality

Limitations in measuring **alpha emitters** directly requires a focus on maintaining **quality control in the clinics** following global shipment. Crucial to the success and safety of your drug is the **analytical testing** to ensure **quality product** is administered to patients. Beyond maintaining drug quality, investigations are ongoing to understand what happens following radiopharmaceuticals **accumulating in the target** and subsequent decay pathways.
Experts will dive into discussions on:

- Understanding how to **measure drug product quality** when unable to measure alpha daughters
- Rapid identity testing of antibody-based hot targeted radionuclide therapies by bio-layer interferometry
- Maintaining **traceability**
- Exploring what innovations could help measure quality
- Investigating potential **systemic toxicity** effects

Laurent Durous, Process Analytical Technology Scientist, **Bayer**

Isaac Simmonds, Associate Director of Radiochemistry, **RayzeBio**

4.00 End of Pre-Conference Workshop Day

Conference Day One | Wednesday, 4th December

7.30 **Check-In, Coffee & Light Breakfast**

Ming Xu
Vice President, Product Team Leader (PTL) for RED Oncology
Bayer

8.20 **Chair's Opening Remarks**

An Evolving European Market: Analysing the Growing Radiopharmaceuticals Field

Evrim Gurpinar
Senior Director, Oncology R&D Business Development
AstraZeneca

8.30 **Breaking Down the Radiopharmaceuticals Landscape & Building on Learnings to Accelerate the Growing Field**

- Uncovering progress made by key European radiopharmaceutical developers and analysing the current landscape
- Drawing comparisons to the ADC space and touching on areas where key lessons could benefit the field with commercial and market insights for future outlooks
- Strengthening therapeutic potential of TRPs through ADC combination and sequencing approaches

Chris Leamon
Chief Scientific Officer
Fusion Pharmaceuticals

9.00 **Advancing Fusion's Targeted 225 Ac Platform- A Glimpse at What's Clinically Advancing & What's to Follow post the AstraZeneca Acquisition**

- Outlining why 225Ac remains an attractive radioisotope for targeted therapy
- Uncovering strategies for antibody-based radiotherapy
- Navigating clinical strategy and updates on Fusion's antibody and small molecule programs, including FPI-2265 (phase 2/3 study)

Goekben Koca
Chief Medical Officer
Mariana Oncology

9.30 **The Mariana Oncology Story-from Conception to Acquisition: Exploring Platform Technologies & First preclinical data.**

- Sharing on the second preclinical stage acquisition to date.
- Exploring platform technologies: optimized ligand technology
- Appreciating th value for patients bringing innovative medicines fast to the patient by collaboration of biotech with big pharma.

10.00 **Morning Break & Speed Networking**

A prime chance to make the most of in-person networking and forge new connections with an expanding community of experts in the radio-pharmaceutical field. Designed to maximise your introduction to numerous new individuals and serve as a catalyst for ongoing discussions during the summit.

Preclinical & Translational Track

Uncovering Trailblazing Preclinical Developments Opening up Novel Directions for the Radiopharmaceuticals Field

11.30 Transforming Cancer Treatment: Advancing Radiopharmaceuticals with Nanomedicine for Enhanced Efficacy

- Revealing aKen Medical's nanoparticles for enhance radiopharmaceutical efficacy by delivering more radionuclide payloads to the targeted tumour
- Improving tumour targeting by directly coupling to vectors
- Enabling simultaneous imaging and therapy, facilitating precise dosimetry to predict treatment outcomes

Laila Quere, Co-founder & Chief Executive Officer, **aKen Medical**

Clinical & Supply Chain Track

Transforming Clinical Understandings to Accelerate Radiopharmaceutical Development & Expand Treatment Efficacy

11.30 Revealing Clinical Design & Early Data from Lead AB001 Programme

- Understanding the mechanisms of action and optimising dose escalations
- Uncovering first in human design post phase 0
- Exploring immunological pathways stimulated

Vicki Jardine, Vice President - Clinical Development, **ARTBIO**

Conference Day One | Wednesday, 4th December

12.00 Session Reserved For: BIOEMTECH

12.15 Roundtables: Exploring Novel Radiopharmaceutical Treatment Modalities:

- Future Applications & Challenges
- From NSCLC, Ovarian Cancer, Breast Cancer, Colorectal Cancer & more
- Outlining the opportunities in each indication
- Identifying challenges in application

12.30 DNA-Encoded Chemical Libraries for the Discovery of Radioligand Therapeutics Targeting FAP & ACP3

- Exploring platform technology
- Navigating new targets
- Pre-clinical lead optimisation

Samuele Cazzamalli, Head of Chemistry, **Philochem**

12.00 Session Reserved For: RPO scientific

12.15 Roundtables: Looking Toward Potential Latent Toxicities for PSMA TRPs Discussing preventative steps

- As more patients are receiving PSMA radiopharmaceuticals, more monitoring is required
- Examining radiation dose and potential secondary malignancies
- Discussing preventative steps

12.30 Identifying Patient Responders & Non-responders Through CXCR4 Targeted Theranostic Approaches for Central Nervous System Lymphoma (CNSL)

- Uncovering the dose-finding clinical phase I/II study
- Predicting treatment responses
- Sharing clinical design

Dirk Pleimes, Chief Medical & Scientific Officer, **PentixaPharm**

1.00 Lunch Break & Networking

Preclinical & Translational Track

Ensuring Translational Succes from Animal to Human Through Strategic Study Design & Expert Rationale

2.00 Industry Sponsored & Investigator-driven Trials: The Best of Both Worlds

- Assessing safety, pharmacokinetics, dosimetry and preliminary efficacy signals of novel radiopharmaceuticals
- Aligning objectives and patient selection
- Exploring Lessons learned for future trial designs

Jens De Vos, Head of Alliance & Program Management, **Precirix**

2.30 Session Reserved For: Navigo Proteins PURE PRECISION

2.45 From Innovation to Implementation: Preclinical Development & Clinical Trial Design for 177Lu-AKIR001

- Navigating the process of transitioning from early preclinical research to initiating clinical trials
- Evaluating the compound's effectiveness and safety, regulatory considerations
- Assessing strategic considerations for designing effective clinical trials

Marika Nestor, Chief Executive Officer, **Akiram Therapeutics**

Clinical & Supply Chain Track

Securing Radioisotope Production Capabilities to Maximise Development

2.00 Uncovering Novel Pb212 Isolation Technologies for Accelerated Production: High Yield Approaches

- New generator technologies among optimised protocol will accelerate production
- Outlining processes on the forefront of development

Daniel Rosetto, Senior Vice President- Head of Supply Chain & External Manufacturing, **ARTBIO**

2.30 Session Reserved For: PharmaLogic Take The Lead

2.45 Changing Manufacturing Processes to Improve Consistency of Radiopharmaceutical Drug Products

- Understanding challenges associated with intermediates characterisation
- Navigating regulatory challenges associated with changes in manufacturing processes
- Assessing cost/benefit analysis of improved processes

Vimal Patel, Vice President, CMC, **RadioPharm Theranostics**

Conference Day One | Wednesday, 4th December

3.15 Maximising Radiopharmaceutical Development Through In-silico Modelling

- Outlining proprietary in-silico model
- Identifying optimal targeting approaches to be implemented
- Assessing isotope and chelator selection

Michel Afargan, Head of Drug Development, **Starget Pharma**

3.15 Interrogating Dose Limits to Push Beyond External Beam Dosing

- Exploring the recent FDA workshop and key dosimetry takeaways from discussions
- How do our technologies and analytical expertise need to improve to bring new regulations?
- Considering practical considerations for implementing in the clinic

Jenny Karlsson, Senior Director Targeted Radiopharmaceuticals, **Bayer**

3.45 Afternoon Break & Scientific Poster Session

This is an informal session to help you connect with your peers in a relaxed atmosphere to continue forging new and beneficial relationships. With an audience of TRP/RLT experts eager to hear the latest drug delivery innovations, you will have the opportunity to display a poster presenting your own research. Don't miss out on the chance to connect, learn, and present.

Maximising Dosimetry Data to Optimise Dosing & Improve Patient Outcomes While Assessing European Funding

4.15 Panel Discussion: Integrating Dosimetry into Clinical Practice for Clinical Trials & Service

- Exploring how implementing dosimetry will lead to more effective treatments and outcomes for practitioners and patients
- Developing dosimetry methodology for new products/indications for standardised practise and maintained regulatory compliance
- Establishing dose limits with a better understanding of the drug for enhanced patient safety and efficacy
- Exploring personalised treatment planning

Munir Ghesani
Chief of Nuclear Medicine
United Theranostics

Katarina Sjögreen Gleisner
Professor
Lund University

Glenn Flux
Head of Radioisotope Physics
Institute of Cancer Research & Royal Marsden Hospital

Jenny Karlsson
Senior Director Targeted Radiopharmaceuticals
Bayer

4.45 Session Reserved For: itm PASSION FOR PRECISION

5.15 Panel Discussion: Challenges and Opportunities for Securing Ongoing Funding for Radiopharmaceuticals in Europe

- Assessing differences in US market
- Understanding nuances in European market to appreciate what investors are looking for
- Hearing what investors are looking for to secure new funding

Jeevan Virk
RLT Therapeutic Area Strategy Head
Novartis

Evrim Gurpinar
Senior Director, Oncology R&D Business Development
AstraZeneca

Ming Xu
Vice President, Product Team Leader (PTL) for RED Oncology
Bayer

5.45 Chair's Closing Remarks

5.50 End of Conference Day One

Conference Day Two | Thursday, 5th December

7.20 **Check-In, Coffee & Light Breakfast**

Goekben Koca
Chief Medical Officer
Mariana Oncology

8.20 **Chair's Opening Remarks**

Shaping Healthcare Policy & Regulations & Engaging Hospitals to Expand Access Across More Patients in Need

8.30 **Transforming the Lives of Patients Through Precision Radiopharmaceuticals: Patient & Health Care System Stories**

- Learn about the positive impact radiopharmaceuticals are having on patient communities
- Hear from clinicians who have seen radiopharmaceuticals on boarded in hospitals and breaking down misconceptions
- Garner key insights to transform your clinical design and improve patient engagement

Ken Herrmann
Professor
University Hospital Essen

Leonhard Schaetz
International Head Health System Readiness & Partnership (RLT)
Novartis

9.00 **Panel Discussion: Obstacles & Opportunities in the Pricing & Reimbursement of Radiopharmaceuticals Across European Countries - Comparing UK, France & Germany**

- Influencing key decision makers within hospitals and how these feeds into healthcare policy making and, ultimately, further patient access
- Sharing experiences of industry-hospital collaborations
- Making legislation, regulation and policy making and how this came about in Europe

Ken Herrmann
Professor
University Hospital Essen

Jasminka Taleska
Global Director RLT HCS Readiness & RLT Policy Strategy
Novartis

Vineet Prakash
Medical Consultant
Royal Surrey NHS Foundation Trust

Caroline Stokke
Associate Professor
Oslo University Hospital

9.30 **Outlining the EANM Guidance Document: Dosimetry for First-in-human Studies & Early Phase Clinical Trials**

- Exploring different emitters and carrier molecules
- Outlining methods for activity measurement, pharmacokinetic analyses, as well as absorbed dose calculations and uncertainty analyses
- Discussing the optimal use of preclinical information and studies involving diagnostic analogues

10.00 **Morning Break & Networking**

Conference Day Two | Thursday, 5th December

Preclinical & Translational Track

Finetuning Dosing & Toxicity Considerations for Radiopharmaceuticals to Ensure Patient Safety

11.30 Optimising Dosing in Translational Radiopharmaceutical Studies

- Using dosimetry to help determine dosing
- Optimising treatment regimens
- Preclinical screening and computational modelling

Francesco De Rose, Head of Pharmaceutical Development, **Nuclideum**

12.00 Innovation Spotlight

- Your chance to see the latest technologies being applied to preclinical radiopharmaceutical development
- Observe and get to know 3 innovative new solutions in this lightning-round technical demonstration

2.15 Exploring Affibody Molecules as Vehicles for Molecular Radiotherapy of HER2-expressing Malignancies: ABY-025 for Patient Selection & ABY-271 for Radioligand Therapy

- Selecting patients by immunohistochemistry has limitations and image-guided decisions have recently proven superior
- Using the PET tracer ABY-025 todemonstrated correlation with improved treatment response prediction and can be translated therapeutically using linker technology for improved kinetics
- ABY-271 is a candidate in late preclinical development for molecular radiotherapy of HER2 expressing cancers

Nina Eissler, Director Translational Medicine, **Affibody**

Clinical & Supply Chain Track

Strengthening Your Radiopharmaceutical Production & Transport Expertise to Ensure no Trial Hold Up

11.30 Streamlining Your Radiopharmaceuticals Logistics Chains to Deliver Quality Drug Product to Patients on Time

- Exploring drug product release and quality assurance
- Optimising transport, tracking and delivery to ensure your drug doesn't get hold up
- Uncovering tracking methods to streamline with patient

Neydher Berroteran-Infante, Director - Chemistry, Manufacturing & Controls, **PentixaPharm**

12.00 Session Reserved For: PSI

12.15 Panel Discussion: A Supply Chain Lens: Exploring Isotope Viability from Production Challenges to Market Potential

- Assessing various isotopes and their supply challenges from continuing lutetium supply to actinium and lead
- Market potential and competition across isotope development
- Solutions for newer companies in the field

Neydher Berroteran-Infante, Director - Chemistry, Manufacturing & Controls, **PentixaPharm**

Vimal Patel, Vice President, CMC, **RadioPharm Theranostics**

Caitlyn Harvey, Vice President, Head of CMC, **Convergent Therapeutics**

12.45 Lunch Break & Networking

Preclinical & Translational Track

Supercharging the Field by Exploring Novel Radiopharmaceutical Targets

1.45 Radionuclide Therapy Improvement Using Radiosensitizers: Preclinical Studies & Future Outlook

- Showcasing various preclinical studies (*in vitro* and *in vivo*)
- Addressing different combination treatments of 177Lu-based radionuclide therapies and agents such as DNA damage repair inhibitors
- Discussing cellular mechanisms and how to use this knowledge to design future (clinical) combination studies

Julie Nonnekens, Associate Professor, **Erasmus MC**

Clinical & Supply Chain Track

Expanding Combination Based Approaches to Maximise Clinical Efficacy of TRPs

1.45 Panel Discussion: Phase 0 for Radiopharmaceuticals: Benefits & Risks

- Uncovering the rationale behind conducting these preliminary studies
- Exploring the pharmacokinetic and pharmacodynamic data it can provide
- Considerations for initiating a phase 0 trial

Sigal Cusnir, Chief Executive Officer, **Starget Pharma**

Conference Day Two | Thursday, 5th December

2.15 Optimising Dosing in Translational Radiopharmaceutical Studies

- Using dosimetry to help determine dosing
- Optimising treatment regimens
- Preclinical screening and computational modelling

Francesco De Rose, Head of Pharmaceutical Development, **Nuclideum**

2.15 Bringing Novel Targets to the Clinic

- Novel target selection to expand use in different solid tumors
- Vector selection: Small molecules or mAb or both?
- Sharing topline clinical imaging data

Riccardo Canevari, Chief Executive Officer, **RadioPharm Theranositcs**

2.45 Afternoon Break & Networking

Amplifying the Field: Spanning More Targets & Advancing Indications with Radiopharmaceuticals

Manfred Rüdiger
Chief Executive Officer
Ariceum

3.15 Assessing Future Directions for Addressing Unmet Medical Need by Expanding Indications & Selecting Novel Targets

- Identifying existing targets to be adapted to radiopharmaceuticals
- Exploring areas of unmet need and market potential
- Uncovering market predictions

Marc Robillard
Chief Executive Officer
Tagworks Pharma

2.45 Illuminating Advances in Click - Cleavable Radioimmunotherapy Programme

- Increasing efficacy and decreasing toxicity with click chemistry
- Ensuring off-target deactivation of unwanted circulating radiopharmaceuticals

Goekben Koca
Chief Medical Officer
Mariana Oncology

4.15 Chair's Closing Remarks

4.25 End of Conference

Partner With Us

Your Platform to Foster New & Existing Relationships Within the Fast-Evolving Radiopharmaceuticals Field

As the field erupts, addressing more areas of unmet medical need, key radiopharmaceutical developers require strong expertise to develop their pipelines from discovery to approval. Being the longest standing industry-focused meeting in the space, **our community of attendees want to meet the service providers who help the field grow.**

Why Partner?

- **Amplify your brand** within the busy landscape, distinguish yourself from the crowd and build trust with your industry to become the go-to radiopharmaceutical service provider to advance drug development
- **Generate commercial opportunities** and meet distinguished radiopharmaceutical leaders or rising stars who are looking for cutting-edge technologies and services to expand their pipeline
- **Uncover crucial market trends** to guide your business strategies in this growing arena
- **Showcase your technical know-how** to key decision-makers and engage in productive conversation

Take the Spotlight - Partnership Opportunities Include:

Data-driven or Case Study led Presentations to position yourself as a thought-leader

Exclusive access to the Delegate List to plan your 1-2-1 conversations in advance

Hosted Lunch, Drinks Reception and Dinner for exclusive time with your target audience

On-site and Web Branding to highlight your company at the forefront of this space

Expert Panel Inclusion to shape forward-thinking discussions

Exhibition Booth to raise brand awareness and answer questions from prospect customers

Organised Networking to generate commercial collaborations

SENIORITY OF ATTENDEES*



- Chief/CXO- 21%
- President/VP- 11%
- Director/Head- 29%
- Manager- 19%
- Other- 20%

TYPES OF COMPANIES ATTENDING*



- Drug Developer
- Healthcare Providers
- Research Institute
- Equipment & Service Providers
- Other

*Based on similar events within the 5th TRP Europe

2024 Partners

Expertise Partner

ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our nearly two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life

www.itm-radiopharma.com

Hosting Partner

PSI is a unique global CRO with offices and an operational presence of full-time operational staff in more than 50 countries. PSI is headquartered in Switzerland and is fully owned by the management team that created the company in 1995.PSI is known for its commitment to delivery and service, focus on global pivotal phase II and III trials, as well as exceptionally high repeat business rates.Biotech and pharma clients that work with PSI on global trials tend to stay with them for decades, which explains the company's stability and steady organic growth supported by exceptionally low staff turnover rates. PSI's mission is to be the best CRO in the world as measured by their employees, clients, investigators, and vendors.

https://psi-cro.com

Innovation Partner

BIOEMTECH is a fast-growing CRO that provides high-quality, cost-effective solutions through the unique combination of preclinical services and molecular imaging instrumentation. BIOEMTECH undertakes full studies for evaluating new compounds in our authorised laboratories. Moreover, BIOEMTECH has developed and commercialised the "eyes", desktop cameras, suitable for whole-body, real-time imaging of radionuclides and dyes in mice. Very recently, BIOEMTECH "eyes" made feasible in vivo imaging of alpha emitters including Pb-212 and Ac-225 in oncological mouse models.

www.bioemtech.com

Innovation Partner

Navigo Proteins is developing novel targeted radiopharmaceuticals based on its proprietary target binders called Affilin® ligands. Navigo's Precision Targeting Toolbox enables custom-designing Affilin® Radiotheranostics by combining, mono-, bi- or multi-specific target binders with chelators, imaging/therapy radionuclides and proprietary half-life extending domains, creating the ideal candidate with fine tuneable affinity and pharmacokinetic profile. With a growing portfolio of Affilin® ligands against solid tumors and I/O targets, Navigo is looking for strategic partnerships to advance Affilin®-Radiotheranostics into clinical development.

www.navigo-proteins.com

Innovation Partner

PharmaLogic is a world-class contract development and manufacturing organization specializing in novel diagnostic imaging and therapeutic radiopharmaceuticals for the treatment of cancers and other diseases. PharmaLogic has decades of expertise in drug development from discovery to commercialization through atop-tier network of radiopharmacies in North America. The Company seeks to take the lead in the advancement of radiopharmaceutical technology for the benefit of patients worldwide. For more information, visit:

www.radiopharmacy.com

Innovation Partner

RPO Group is a boutique CRO focusing on supporting early phase radiopharmaceutical drug development aiming to bring innovative radiotheranostic agents to cancer patients, and increase their treatment options.

RPO Group's core services include clinical operations, imaging, and dosimetry which are all services key to the execution of radiopharmaceutical trials. RPO Group also offers strategic and scientific advice, regulatory support, medical writing, and medical monitoring.

RPO Group has the capability to manage client's needs by leveraging its global network of preferred sites for trial execution and utilizing their preferred partners in radio(pharmaceutical) manufacturing.

www.rpo-scientific.com

2024 Partners

Innovation Partner

SHINE Technologies, based in Janesville, Wisconsin, is pioneering next-generation fusion technology for medical isotope production. Specializing in n.c.a. lutetium-177 and soon, molybdenum-99, SHINE aims to revolutionize cancer treatment and diagnostics. Their innovative fusion-based approach drives advancements across multiple sectors, including healthcare and sustainable energy solutions.

www.shinefusion.com

Innovation Partner

Chelatec was founded in 2000 by seasoned scientists trained in the development of radiopharmaceuticals. Experts in the use of radioactive tracers, they decided to offer their knowledge in preclinical development of targeted radiotherapeutics to pharma and biotech.

With state-of-the-art fully equipped laboratories for radiolabeling, radioanalyses, handling of cells and housing of animals, Chelatec is recognized for its reliable expertise and offers a unique combination of custom radiolabeling, in vitro assays and in vivo investigations capabilities.

Specializing in radiopharmaceutical R&D, Chelatec will provide you with information on your Investigational Medicinal Product to be part of the documentation package: all quality and non-clinical safety data required for translation of a radiopharmaceutical.

www.chelatex.com

Innovation Partner

Trasis was founded in 2004 by Gauthier Philippart and Jean-Luc Morelle, the designers of the first radiosynthesisers to combine high-yield synthesis and GMP.

They put together their expertise and their knowledge of the radiopharmaceutical industry and founded Trasis, an innovative and forward-looking company. Trasis has now a track-record in developing instruments and methods recognized throughout the world.

At Trasis we are dedicated to helping the medical community access new radio-labelled therapeutic and diagnostic substances easily and faster. To this end, we design, manufacture, sell and support high performance synthesisers, dose preparation equipment, their shielding and accessories. We also develop customised synthetic methods and instruments. We can provide GMP Active Pharmaceutical Ingredients (API) and assist our customers with their regulatory affairs.

Our proven radiopharmaceutical expertise, coupled with our high end instruments allow us to provide fully integrated solutions for an effective tracer production and faster transition from drug development to marketing authorisation.

Our equipment is used worldwide in nuclear medicine departments, research centers, radiopharmaceutical production facilities and pharmaceutical companies

www.trasis.com

Exhibition Partner

IONETIX is a full-service, end-to-end radiopharmaceutical solutions provider. Utilizing a proprietary cyclotron technology platform, Ionetix develops innovative accelerator solutions to produce medical radioisotopes used for both diagnostic and therapeutic radiopharmaceuticals. Ionetix is currently in the process of establishing the first commercial alpha isotope manufacturing and distribution facility dedicated to the production of Actinium-225 (Ac- 225) and Astatine-211 (At- 211). Ionetix will provide isotope production, drug manufacturing and distribution logistics for these alpha isotopes beginning in early 2023

www.ionetix.com

Exhibition Partner

We provide pharmaceutical design and qualification consultancy, as well as qualification and validation for high value manufacturing, research, emerging technologies and highly regulated industries; this includes pharmaceutical, biotechnology, life sciences and radiopharmaceutical industries. We have a multidisciplinary team, with extensive experience across pharmaceutical design and qualification consultancy, cell gene therapy and animal health, to name a few.

www.scitech.com

2024 Partners

Event Partner

Leveraging over seven years of expertise in the GMP manufacturing and global distribution of radiotherapeutics, the Centre for Probe Development and Commercialization (CPDC) is launching AtomVie Global Radiopharma Inc. (AtomVie), a global leading Contract Development and Manufacturing Organization (CDMO). AtomVie offers the full range of scientific, technical, regulatory, quality, logistics, and Lu-177 supply combined with a specialized infrastructure for the development of your radiotherapeutics from clinical Phase 1 to the commercial marketplace.

www.atomvie.com

Event Partner

NorthStar Medical Radioisotopes is a commercial-stage nuclear medicine company focused on advancing patient care by providing therapeutic and diagnostic radioisotopes, novel radiopharmaceuticals and customized radiopharmaceutical development services. Its proven management team and environmentally preferable, non-uranium based technologies have made it an emerging leader at the forefront of U.S. medical radioisotope and radiopharmaceutical production. NorthStar is poised to be the first commercial-scale producer of non-carrier added (n.c.a.) actinium-225 (Ac-225) and copper-67 (Cu-67). Its Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO/CMO) services unit will provide customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance their programs.

www.northstarnm.com

Event Partner

Established in 2002, time:matters has emerged as a leader in customized and flexible logistics solutions. At time:matters, we specialize in high-performance logistics, providing time-critical solutions worldwide. From urgently needed spare parts to medical samples, dangerous goods, and important documents, we offer dedicated, reliable, and efficient transportation options via air, rail, and road.

Our comprehensive expertise seamlessly integrates and combines multiple modes of transport, ensuring flexibility and timely delivery. Whether it is a critical component for the automotive industry or life-saving stem cells, we deliver solutions you can trust, because we understand the requirements of your shipments and are dedicated to meeting them.

www.time-matters.com/

> "Very good workshop sessions and networking opportunities"
>
> **Clovis Oncology**

Ready to Register?

3 Easy Ways To Book

www.targeted-radiopharma.com/register

Tel: +44 (0)20 3141 8700

Email: info@hansonwade.com

1. **DISCOVER** what's at the forefront of radiopharmaceutical innovation with key industry members pioneering the field, from moving the needle in clinical research to solving supply chain challenges.
2. **DELIVER** more drugs to the lives of patients in need. From continuing development across mature development and optimizing capabilities to exploring new directions in the field to find new targets across more indications
3. **ENGAGE** with your community and peers from leading pharma and most exciting up and coming biotech companies to build lasting connections, complementary collaborations and seeking the best solution to radiopharmaceuticals

Team Discounts

- 10% discount – 2+ Attendees
- 15% discount – 3+ Attendees
- 20% discount – 4+ Attendees

**Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

Industry Pricing	Register & Pay By Friday, 25th October	On the Door Price
Conference + Workshop Day	€3,197 **(Save €600)**	€3,797
Conference Only	€2,399 **(Save €400)**	€2,799

Academic & Non-Profit Pricing	Register & Pay By Friday, 25th October	On the Door Price
Conference + Workshop Day	€2,597 **(Save €600)**	€3,197
Conference Only	€1,999 **(Save €400)**	€2,399

Solution Provider	Register & Pay By Friday, 25th October	On the Door Price
Conference + Workshop Day	€3,997 **(Save €600)**	€4,597
Conference Only	€3,099 **(Save €400)**	€3,399

*To qualify for the drug developer rate your company must have a public drug pipeline. Please visit the website for full pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

**To qualify for academic & research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Please select the appropriate price when booking. Bookings are subject to approval. If you are a UK or EU-based company, you may be subject to 21% VAT in addition to the price advertised. If you qualify for a reverse charge, you will have the option to provide your VAT number and the charge will be automatically deducted at checkout. If you have any questions, please get in touch at info@hansonwade.com or call +44 (0)20 3141 8700

Venue

Leonardo Royal Hotel, Amsterdam

Paul van Vlissingenstraat 24, 1096 BK Amsterdam, Netherlands

https://www.leonardo-hotels.com/amsterdam/leonardo-royal-hotel-amsterdam

BOOK BY FRIDAY, 25TH OCTOBER & SAVE €600

CONTENTS

WELCOME

AGENDA AT A GLANCE

EXPERT SPEAKERS

PRE-CONFERENCE WORKSHOP DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

PARTNER WITH US

PARTNERS